Oak Ridge Investments LLC decreased its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 11.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 729,874 shares of the biopharmaceutical company’s stock after selling 91,196 shares during the quarter. Sage Therapeutics comprises about 1.9% of Oak Ridge Investments LLC’s investment portfolio, making the stock its 11th biggest position. Oak Ridge Investments LLC owned about 1.95% of Sage Therapeutics worth $58,127,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in shares of Sage Therapeutics by 1.1% during the first quarter. Principal Financial Group Inc. now owns 5,623 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 62 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Sage Therapeutics by 11.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 138 shares during the last quarter. Keybank National Association OH boosted its holdings in shares of Sage Therapeutics by 10.6% during the second quarter. Keybank National Association OH now owns 3,798 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 363 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in shares of Sage Therapeutics by 5.7% during the second quarter. State Board of Administration of Florida Retirement System now owns 12,742 shares of the biopharmaceutical company’s stock worth $1,015,000 after purchasing an additional 686 shares during the last quarter. Finally, Essex Investment Management Co. LLC boosted its holdings in shares of Sage Therapeutics by 2.5% during the second quarter. Essex Investment Management Co. LLC now owns 31,660 shares of the biopharmaceutical company’s stock worth $2,521,000 after purchasing an additional 787 shares during the last quarter.

Sage Therapeutics, Inc. (NASDAQ SAGE) traded up 0.47% on Friday, reaching $87.00. The company’s stock had a trading volume of 500,701 shares. The stock has a 50 day moving average price of $82.92 and a 200-day moving average price of $74.51. Sage Therapeutics, Inc. has a 1-year low of $38.30 and a 1-year high of $90.80. The company’s market capitalization is $3.26 billion.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($1.63) by $0.25. During the same quarter last year, the firm posted ($1.08) EPS. Equities analysts predict that Sage Therapeutics, Inc. will post ($7.38) earnings per share for the current fiscal year.

A number of brokerages recently weighed in on SAGE. J P Morgan Chase & Co reiterated a “buy” rating on shares of Sage Therapeutics in a report on Thursday, August 31st. Cowen and Company reiterated a “buy” rating and issued a $100.00 target price on shares of Sage Therapeutics in a report on Friday, August 4th. BidaskClub cut Sage Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Needham & Company LLC began coverage on Sage Therapeutics in a report on Monday, May 15th. They issued a “buy” rating and a $82.00 target price on the stock. Finally, HC Wainwright lifted their target price on Sage Therapeutics to $86.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $89.64.

ILLEGAL ACTIVITY WARNING: “Oak Ridge Investments LLC Has $58.13 Million Stake in Sage Therapeutics, Inc. (SAGE)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/10/oak-ridge-investments-llc-has-58-13-million-stake-in-sage-therapeutics-inc-sage.html.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc. (NASDAQ:SAGE).

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.